Rezny Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 6,472 shares of the company’s stock, valued at approximately $1,133,000. Johnson & Johnson comprises about 0.4% of Rezny Wealth Management Inc.’s investment portfolio, making the stock its 22nd biggest position.
Other institutional investors also recently bought and sold shares of the company. DORCHESTER WEALTH MANAGEMENT Co lifted its stake in Johnson & Johnson by 8.6% during the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after acquiring an additional 5,327 shares during the period. Cantor Fitzgerald Investment Advisor L.P lifted its stake in Johnson & Johnson by 88.9% during the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after acquiring an additional 82,429 shares during the period. IFM Investors Pty Ltd lifted its stake in shares of Johnson & Johnson by 20.1% in the 1st quarter. IFM Investors Pty Ltd now owns 418,999 shares of the company’s stock worth $74,259,000 after purchasing an additional 70,221 shares during the period. Essex LLC lifted its stake in shares of Johnson & Johnson by 3.7% in the 1st quarter. Essex LLC now owns 32,274 shares of the company’s stock worth $5,720,000 after purchasing an additional 1,146 shares during the period. Finally, Hardy Reed LLC lifted its stake in shares of Johnson & Johnson by 2.7% in the 1st quarter. Hardy Reed LLC now owns 5,098 shares of the company’s stock worth $904,000 after purchasing an additional 133 shares during the period. 68.59% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
JNJ has been the topic of several recent research reports. Raymond James lowered their price objective on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 19th. Barclays initiated coverage on shares of Johnson & Johnson in a research note on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price objective on the stock. Morgan Stanley lowered their price objective on shares of Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 19th. Citigroup lowered their price objective on shares of Johnson & Johnson from $201.00 to $198.00 in a research note on Wednesday, October 5th. Finally, Atlantic Securities reduced their target price on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Wednesday, October 19th. Seven investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $181.33.
Insider Buying and Selling at Johnson & Johnson
Johnson & Johnson Trading Up 0.5 %
Shares of JNJ opened at $176.82 on Wednesday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The company has a 50 day simple moving average of $168.35 and a two-hundred day simple moving average of $171.28. The firm has a market cap of $462.29 billion, a P/E ratio of 24.63, a price-to-earnings-growth ratio of 3.49 and a beta of 0.57.
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The business had revenue of $23.79 billion during the quarter, compared to analyst estimates of $23.44 billion. During the same period last year, the firm posted $2.60 EPS. The company’s revenue was up 1.9% on a year-over-year basis. On average, equities analysts expect that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be issued a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.56%. The ex-dividend date is Monday, November 21st. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.95%.
Johnson & Johnson announced that its Board of Directors has initiated a share repurchase program on Wednesday, September 14th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the company to repurchase up to 1.2% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Want to Get a 10% Dividend Yield, Look Here
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.